

CLINICAL SCIENCE

The modified Hodge test is a useful tool for ruling out *klebsiella pneumoniae* carbapenemase

Ana Paula Cury,^I Denise Andreazzi,^{II} Márcia Maffucci,^{III} Hélio Hehl Caiaffa-Junior,^{III} Flávia Rossi^I

^IHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Pathology Department, Microbiology Laboratory, DLC-LIM 03, São Paulo/SP, Brazil. ^{II}Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Pathology Department, Telemedicine Laboratory, São Paulo/SP, Brazil. ^{III}Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Pathology Department, Molecular Biology Laboratory, DLC-LIM 03, São Paulo/SP, Brazil.

OBJECTIVE: *Enterobacteriaceae* bacteria harboring *Klebsiella pneumoniae* carbapenemase are a serious worldwide threat. The molecular identification of these pathogens is not routine in Brazilian hospitals, and a rapid phenotypic screening test is desirable. This study aims to evaluate the modified Hodge test as a phenotypic screening test for *Klebsiella pneumoniae* carbapenemase.

METHOD: From April 2009 to July 2011, all *Enterobacteriaceae* bacteria that were not susceptible to ertapenem according to Vitek2 analysis were analyzed with the modified Hodge test. All positive isolates and a random subset of negative isolates were also assayed for the presence of *bla*_{KPC}. Isolates that were positive in modified Hodge tests were sub-classified as true-positives (*E. coli* touched the ertapenem disk) or inconclusive (distortion of the inhibition zone of *E. coli*, but growth did not reach the ertapenem disk). Negative results were defined as samples with no distortion of the inhibition zone around the ertapenem disk.

RESULTS: Among the 1521 isolates of *Enterobacteriaceae* bacteria that were not susceptible to ertapenem, 30% were positive for *bla*_{KPC}, and 35% were positive according to the modified Hodge test (81% specificity). Under the proposed sub-classification, true positives showed a 98% agreement with the *bla*_{KPC} results. The negative predictive value of the modified Hodge test for detection was 100%. KPC producers showed high antimicrobial resistance rates, but 90% and 77% of these isolates were susceptible to aminoglycoside and tigecycline, respectively.

CONCLUSION: Standardizing the modified Hodge test interpretation may improve the specificity of KPC detection. In this study, negative test results ruled out 100% of the isolates harboring *Klebsiella pneumoniae* carbapenemase-2. The test may therefore be regarded as a good epidemiological tool.

KEYWORDS: Modified Hodge Test; KPC; Carbapenemase; Ertapenem.

Cury AP, Andreazzi D, Maffucci M, Caiaffa-Junior HH, Rossi F. The modified Hodge test is a useful tool for ruling out *klebsiella pneumoniae* carbapenemase. Clinics. 2012;67(12):1427-1431.

Received for publication on August 3, 2012; First review completed on August 24, 2012; Accepted for publication on August 28, 2012

E-mail: anapaulacury@gmail.com

Tel.: 55 11 2661-6136/6348

INTRODUCTION

Carbapenems are one of the last remaining antimicrobial treatments for multidrug-resistant *Enterobacteriaceae*, and resistance to this class of antibiotics is becoming a threat worldwide (1). Impermeability due to porin loss concomitant with the hyperproduction of cephalosporinases is often the cause of carbapenem resistance, but serine beta-lactamases, such as *Klebsiella pneumoniae* carbapenemase (KPC), are spreading fast and becoming prevalent worldwide (1-3). The genes encoding the KPC enzyme are usually flanked by transposon-related sequences that have been

identified on transferable plasmids, giving these genes the potential to disseminate to other genera and species (4). Currently, KPC producers are found all over the world, with reports from Greece (5), Israel (6), France (7), China (8), and South America (4).

In Brazil, KPC was first described in the northwestern region in 2006 and has become an important mechanism of resistance to carbapenems since then (9-11). In our institution, carbapenem resistance among *Enterobacteriaceae* was only sporadically noted prior to 2005. However, starting in 2008, KPC producers became an epidemiological challenge.

The early recognition of KPC-producing isolates has become necessary due to the clinical and epidemiological implications of the presence of KPC. The routine laboratory detection of KPC is a challenge, especially for laboratories without molecular diagnostic resources, as is common in Brazilian hospitals.

The modified Hodge test (MHT) is a phenotypic screening test for carbapenemases that is used for epidemiological

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

purposes, and its use is currently proposed by the Clinical and Laboratory Standards Institute (CLSI) (12). The MHT is easy to perform, but divergent specificity values have been reported, and false-positive results are a concern (13,14).

The aim of this study was to evaluate the performance of a new proposal for interpreting the modified Hodge test and detect the *bla*_{KPC} gene among *Enterobacteriaceae* isolates, which were collected in our 2500-bed hospital, that exhibited ertapenem MICs ≥ 1 μ g/ml.

MATERIALS AND METHODS

From April 2009 to July 2011, a total of 1521 *Enterobacteriaceae* isolates that were not susceptible to ertapenem (ENSEs), with MICs ≥ 1 μ g/ml from any clinical specimen, were selected from among the patient cultures of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. When more than one isolate was recovered from a patient, the second isolate was only included if it was another species or the same species with a different susceptibility pattern.

Identification and antimicrobial susceptibility testing were performed using a Vitek2 system (bioMérieux Marcy-L'ile, France) with the AST-N105 and AST-N104 cards. Categorical interpretations were performed according to CLSI M100-S21 (12). For colistin, the CLSI breakpoints for *P. aeruginosa* were the reference for categorical interpretation, and the U.S. Food and Drug Administration (FDA) breakpoints were used for tigecycline. All isolates were tested by the MHT according to the CLSI recommendations and quality control.

The results of the modified Hodge test were categorized according to the CLSI recommendations as follows: negative when there was no distortion of the inhibition zone around the ertapenem disk, positive when any distortion of the *E. coli* ATCC 25922 (strain indicator) inhibition zone was noted around the ertapenem disk, and indeterminate when the inhibition of *E. coli* ATCC 25922 growth around the streak (tested strain) was evidenced by a clear area.

All isolates with positive modified Hodge test results were classified using a new sub-classification proposed by our group: A) a result was considered a true-positive when *E. coli* ATCC 25922 touched the ertapenem disk; and B) a result was considered inconclusive when there was distortion of the *E. coli* ATCC 25922 inhibition zone around the ertapenem disk, but the bacteria did not touch the edge of the disk. See Figure 1 for the modified Hodge test sub-classification definition in our study.




Figure 1 - Modified Hodge test (MHT) with ertapenem disks. Interpretation of the MHT results proposed in this study: A) true-positive MHT, B) inconclusive MHT and C) negative MHT.

All isolates with positive and indeterminate modified Hodge test results were submitted to molecular detection of the *bla*_{KPC} gene by PCR. Isolates with negative test results were also randomly chosen for molecular KPC testing. The primers used for PCR amplification and the reaction conditions were described previously (15). The PCR products were visualized by electrophoresis on 2% agarose gels stained with ethidium bromide and visualized with UV light.

Two samples of *bla*_{KPC} amplicons (859 bp) produced by PCR were selected and submitted to DNA sequencing with a BigDye Terminator cycle sequencing kit v3.1 (Applied Biosystems Inc., Foster City, CA) in an MJ Research PTC-200 DNA Engine thermal cycler (Bio-Rad Laboratories, Waltham, USA). The sequencing reaction products were purified by ethanol precipitation, separated, and analyzed using an ABI Prism 3100 genetic analyzer (ABI, Foster City, USA) following the manufacturer's protocols. The sequenced products were compared using software available at the National Center for Biotechnology Information website (<http://blast.ncbi.nlm.nih.gov>).

The antibiograms for KPC producers and non-producers were analyzed. The MIC₅₀ and MIC₉₀ values were calculated using Whonet version 5.4.

The sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated according to the method of Ilstrup (16).

RESULTS

We analyzed 1521 *Enterobacteriaceae* isolates that were not susceptible to ertapenem, of which 30% (458) were positive for *bla*_{KPC}. Among the *bla*_{KPC}-positive isolates, 93% were *Klebsiella pneumoniae*. The modified Hodge test results are summarized according to the species distribution and molecular detection of *bla*_{KPC} in Table 1. The modified Hodge test was positive in 35.5% of *Enterobacteriaceae* isolates that were not susceptible to ertapenem (540), and according to our proposed sub-classification, 71% (386) of those isolates showed true-positive results, and 29% (154) had inconclusive results. The true-positive results showed 98% agreement with the molecular KPC results, whereas the level of agreement for the inconclusive results was only 51%.

The modified Hodge test results according to the sensitivity, specificity and predictive values for KPC detection are shown in Table 2. The modified Hodge test had a 100% negative predictive value.

Specimens yielding KPC-producing isolates were primarily urine samples (37%), rectal swabs (17%), blood samples (10%), and catheters (10%).

The antimicrobial susceptibility profile of the KPC-producing isolates revealed high resistance rates to all cephalosporins, aztreonam (98.9%), piperacillin/tazobactam (99.3%), and fluoroquinolones (92%). Amikacin and gentamycin had susceptibility rates of 95% and 88%, respectively. Tigecycline had an 8% susceptibility rate, and colistin had an MIC₅₀ of 2 mg/l and MIC₉₀ of 4 mg/l. The meropenem results for KPC isolates from the automated system indicated that 50% were resistant, but the disk method indicated that 70% of isolates were resistant (data not shown). The KPC non-producing isolates also had high rates of resistance to all cephalosporins, aztreonam, piperacillin/tazobactam, and fluoroquinolones, and the detailed information is summarized in Table 3.

The DNA sequencing of the KPC-producing isolates confirmed that they carried the KPC-2 variant.

Table 1 - Distribution of 1521 *Enterobacteriaceae* isolates that were not susceptible to ertapenem (ENSE) according to the modified Hodge test (MHT) results and the presence of *bla*_{KPC}.

MHT results ^a N° ENSE	Organism	N° ENSE (<i>bla</i> _{KPC} tested)	<i>bla</i> _{KPC} Negative	<i>bla</i> _{KPC} Positive
Negative 975 (64.1%)	<i>K. pneumoniae</i>	481 (191)	191	0
	<i>E. cloacae</i>	293 (111)	111	0
	<i>E. aerogenes</i>	85 (16)	16	0
	<i>E. coli</i>	62 (22)	22	0
	<i>S. marcescens</i>	15 (8)	8	0
	<i>P. mirabilis</i>	12 (1)	1	0
	<i>M. morgannii</i>	8 (0)	0	0
	<i>C. freundii</i>	7 (4)	4	0
	<i>E. gergoviae</i>	7 (2)	2	0
	<i>K. oxytoca</i>	2 (0)	0	0
	<i>P. stuartii</i>	2 (0)	0	0
	<i>P. vulgaris</i>	1 (0)	0	0
	Total	975 (355)	355 (100%)	0 (0)
Positive 540 (35.5%)	True-positive ^b 386 (71%)	<i>K. pneumoniae</i> (354)	1	353
		<i>E. cloacae</i> (10)	3	7
		<i>E. aerogenes</i> (3)	0	3
		<i>E. coli</i> (6)	0	6
		<i>S. marcescens</i> (6)	3	3
		<i>C. koseri</i> (1)	0	1
		<i>C. freundii</i> (1)	0	1
		<i>E. asburiae</i> (2)	0	2
		<i>K. oxytoca</i> (2)	0	2
		Total (386)	7 (2%)	379 (98%)
	Inconclusive ^b 154 (29%)	<i>K. pneumoniae</i> (111)	40	71
		<i>E. cloacae</i> (26)	24	2
		<i>E. aerogenes</i> (10)	10	0
		<i>E. coli</i> (2)	0	2
		<i>E. gergoviae</i> (2)	2	0
		<i>E. asburiae</i> (1)	0	1
		<i>S. marcescens</i> (2)	0	2
		Total (154)	76 (49%)	78 (51%)
Indeterminate 6 (0.4%)		<i>E. cloacae</i> (4)	3	1
		<i>E. coli</i> (1)	1	0
		<i>K. pneumoniae</i> (1)	1	0
		Total (6)	5 (86%)	1 (14%)
Total: 1521		(901)	443	458

^aPositive, indeterminate, and negative results were defined according to the recommendations of the Clinical and Laboratory Standards Institute.^bTrue-positive and inconclusive results were defined according to this study's proposal (see Figure 1).

DISCUSSION

The presence of *bla*_{KPC} deserves special attention because isolates harboring this plasmid gene are usually multidrug resistant, limiting the therapeutic options available and causing a high mortality rate (17).

KPC represents an epidemiological challenge for infection control groups because it can spread very quickly, and there are limited treatment options available (18). The early detection of such isolates is critical. Screening for KPC producers by identifying *Enterobacteriaceae* isolates that are

Table 2 - Performance of the modified Hodge test (MHT) for KPC detection.

MHT	N° Isolates	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
True-positive	386	100	98	98	100
Inconclusive	154	100	82	51	100
Positive ^a	540	100	81	85	100

^aTrue-positive plus inconclusive results.

PPV - positive predictive value, NPV - negative predictive value.

not susceptible to ertapenem has a low specificity but is a starting point to identify isolates harboring carbapenemases. The modified Hodge test is relatively easy to perform in standard microbiology laboratories, and the standardization of the interpretation of the results may improve the specificity of this test for KPC detection.

Infections caused by KPC-producing isolates are now a concern in our institution, and 30% of the *Enterobacteriaceae* isolates that were not susceptible to ertapenem were KPC positive in this study period. The majority of those isolates (37%) were from urine cultures, but the positivity rate for KPC among blood isolates was proportionally higher (data not shown).

The molecular detection of *bla*_{KPC} is the gold standard for diagnosis, but the majority of standard laboratories in our country do not have the resources necessary to perform this test on a routine basis. Phenotypic tests should be made available to detect KPC early or rule it out. The modified Hodge test may detect the presence of carbapenemases, but it is not specific for KPC and may have false-positive results due to non-carbapenemase enzymes, such as AmpC and/or extended-spectrum beta-lactamases (ESBLs), combined with

Table 3 - *In vitro* activity of antimicrobial agents tested against 901 ENSE isolates.

Antibiotic ^a	KPC producers (458)					KPC non-producers (443)				
	%R	%I	%S	MIC ₅₀	MIC ₉₀	%R	%I	%S	MIC ₅₀	MIC ₉₀
PTZ	99.3	0.7	0	128	128	93.3	2.1	4.6	128	128
Ceftazidime	82.9	5.6	11.5	64	64	91	2	7	64	64
Cefotaxime	94.7	3.7	1.5	64	64	95.9	0.7	3.4	64	64
Cefepime	54.0	23.5	22.5	64	64	68.7	4.6	26.7	64	64
Aztreonam	98.9	0.3	0.8	64	64	93.4	0.8	5.8	64	64
Ertapenem	100	0	0	8	8	99.5	0.5	0	4	8
Imipenem	69.8	16.4	13.8	8	16	22.5	8	69.5	1	8
Meropenem	50	7	43	2	16	27.9	3.6	68.4	0.25	8
Amikacin	3.1	1.5	95.4	2	16	17	3	80	2	64
Gentamicin	11	1	88	1	16	48.3	2.3	49.4	8	16
Ciprofloxacin	92	1	7	4	4	79.5	2.5	18	4	4
SUT	94	0	6	16	16	60.4	0	39.6	16	16
Colistin ^b	32	0	68	0.5	16	11.7	0.5	87.8	0.5	16
Tigecycline ^c	8	15	77	2	4	11	13	76	1	8

^aMinimum inhibitory concentration (MIC) breakpoint in mg/L, as determined by the Vitek2[®] system.

^bBreakpoint for *P. aeruginosa* according to the Clinical and Laboratory Standards Institute.

^cU.S. Food and Drug Administration (FDA) breakpoints.

SUT: trimethoprim/sulfamethoxazole; PTZ: piperacillin/tazobactam; ENSE: *Enterobacteriaceae* not susceptible to ertapenem; KPC: *Klebsiella pneumoniae* carbapenemases; R: resistant; I: intermediate; S: susceptible.

porin loss. Positive results could also be due to other carbapenemases. In the literature, the specificity of the modified Hodge test differs because some authors analyzed data for distinct bacteria groups, such as non-fermenters and *Enterobacteriaceae*, and detected different carbapenemases, such as NDM (13). In our study, the modified Hodge test was evaluated only for *Enterobacteriaceae* bacteria and KPC producers, which may explain the high level of agreement with the molecular results.

The proposed positive modified Hodge test category had 98% agreement with the molecular *bla*_{KPC} results, highlighting the good positive predictive value of KPC detection among *Enterobacteriaceae* when a standardized method for interpretation is in place. Seven isolates showed true-positive results and were negative for *bla*_{KPC}, but an accurate analysis of the reason for these discrepancies was limited because no tests were performed for other carbapenemases. Of the isolates in the inconclusive group, 49% were negative for *bla*_{KPC}, and these negative strains most likely produced CTX-M or hyperproduced AmpC in association with porin loss. Another possibility is that these isolates produced carbapenemases other than KPC.

The indeterminate result, as proposed by the CLSI, does not have a clear microbiological or clinical interpretation in the literature and should be the focus of future studies.

Enterobacteriaceae bacteria that not susceptible to ertapenem but have a negative modified Hodge test result are not KPC producers.

Although tests other than the modified Hodge test, such as the aminophenylboronic acid and dipicolinic acid tests, may also be options for the phenotypic screening for carbapenemases (19), the supplies necessary for these tests are not routinely available in the majority of Brazilian laboratories.

The antibiograms of the 458 KPC isolates generated using the automated system revealed multidrug resistance and showed that 43% of isolates were susceptible to meropenem (MIC ≤1 µg/ml). The meropenem susceptibility rates were not reproducible by TREK microdilution panels (Cleveland, OH) or the disk diffusion method (OXOID) (data not shown), with 45% very major errors (VMEs) for this drug. Corroborating

these findings, the literature contains reports of unacceptable VME levels for meropenem when KPC isolates were tested using automated systems. Microbiologists and clinicians should be aware of the current problems regarding false susceptibility results for meropenem among KPC isolates when only automated systems are used to screen isolates (20). Regarding the colistin and tigecycline Vitek results, our internal validation process did not show major discrepancies with the E-test (data not shown), and published studies have not reported major problems with these drugs (21). Every laboratory should perform its own validation of automated systems when CLSI breakpoints are in place.

The modified Hodge test results for *Enterobacteriaceae* using standardized readings are a useful phenotypic and epidemiological tool to identify KPC isolates while waiting for molecular results. Negative modified Hodge test results ruled out all KPC isolates in our institution in an efficient and timely manner.

AUTHOR CONTRIBUTIONS

Cury AP designed and conducted the study, and was also responsible for the microbiological procedures, data collection, analysis and interpretation, and manuscript drafting. Andreazzi D contributed to the interpretation and presentation of the results, statistical analysis and manuscript review. Maffucci M and Caiaffa-Junior HH conducted the molecular biological procedures. Rossi F mentored Cury AP, conducted the analysis of the results and was also responsible for the manuscript writing, review and approval.

REFERENCES

- Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of *Enterobacteriaceae* isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). *Diagn Microbiol Infect Dis*. 2006;56(4):367-72, <http://dx.doi.org/10.1016/j.diagmicrobio.2006.07.004>.
- Chiang T, Mariano N, Urban C, Colon-Urban R, Grenner L, Eng RH, et al. Identification of carbapenem-resistant *klebsiella pneumoniae* harboring KPC enzymes in New Jersey. *Microb Drug Resist*. 2007 Winter;13(4):235-39.
- Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing *Klebsiella pneumoniae* in Brooklyn, New York: epidemiology and recommendations for detection. *Antimicrob*

- Agents Chemother. 2005;49(7):3018-20, <http://dx.doi.org/10.1128/AAC.49.7.3018-3020.2005>.
4. Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of *Klebsiella pneumoniae* from South America. *Antimicrob Agents Chemother*. 2006;50(8):2880-2, <http://dx.doi.org/10.1128/AAC.00186-06>.
 5. Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2-producing *Klebsiella pneumoniae* in a hospital in Crete (Greece). *J Infect*. 2009;58(3):213-9, <http://dx.doi.org/10.1016/j.jinf.2009.01.010>.
 6. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant *Escherichia coli* clones in Israel. *Antimicrob Agents Chemother*. 2006;50(9):3098-101, <http://dx.doi.org/10.1128/AAC.00438-06>.
 7. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a *Klebsiella pneumoniae* isolate from France. *Antimicrob Agents Chemother*. 2005;49(10):4423-4, <http://dx.doi.org/10.1128/AAC.49.10.4423-4424.2005>.
 8. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a *Klebsiella pneumoniae* isolate from China. *Antimicrob Agents Chemother*. 2007;51(2):763-5, <http://dx.doi.org/10.1128/AAC.01053-06>.
 9. Pavez M, Mamizuka EM, Lincopan N. Early dissemination of KPC-2-producing *Klebsiella pneumoniae* strains in Brazil. *Antimicrob Agents Chemother*. 2009;53(6):2702, <http://dx.doi.org/10.1128/AAC.00089-09>.
 10. Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2-producing *Klebsiella pneumoniae* strains in Brazil. *Antimicrob Agents Chemother*. 2009;53(1):333-4, <http://dx.doi.org/10.1128/AAC.00736-08>.
 11. Andrade LN, Curiao T, Ferreira JC, Longo JM, Climaco EC, Martinez R, et al. Dissemination of blaKPC-2 by the spread of *Klebsiella pneumoniae* clonal complex 258 clones (ST258, ST11, ST437) and plasmids (IncFII, IncN, IncL/M) among *Enterobacteriaceae* species in Brazil. *Antimicrob Agents Chemother*. 2011;55(7):3579-83, <http://dx.doi.org/10.1128/AAC.01783-10>.
 12. Clinical and Laboratory Standards Institute. Performance Standards for antimicrobial susceptibility testing. CLSI document Wayne, PA, USA. 2011;M100-S21.
 13. Girlich D, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in *Enterobacteriaceae*. *J Clin Microbiol*. 2012;50(2):477-9, <http://dx.doi.org/10.1128/JCM.05247-11>.
 14. Carvalhaes CG, Picao RC, Nicoletti AG, Xavier DE, Gales AC. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in *Klebsiella pneumoniae*: be aware of false positive results. *J Antimicrob Chemother*. 2010;65(2):249-51, <http://dx.doi.org/10.1093/jac/dkp431>.
 15. Castanheira M, Sader HS, Jones RN. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing *Enterobacteriaceae*. *Microb Drug Resist*. 2010;16(1):61-5, <http://dx.doi.org/10.1089/mdr.2009.0031>.
 16. Ilstrup DM. Statistical methods in microbiology. *Clin Microbiol Rev*. 1990;3(3):219-26.
 17. Tumbarello M, Viale P, Viscoli C, Trearichi EM, Tumietto F, Marchese A, et al. Predictors of Mortality in Bloodstream Infections Caused by KPC-Producing *Klebsiella pneumoniae*: Importance of Combination Therapy. *Clin Infect Dis*. 2012;55(7):943-50.
 18. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing *Klebsiella pneumoniae* and impact of appropriate antimicrobial treatment. *Clin Microbiol Infect*. 2011;17(12):1798-803, <http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x>.
 19. Pasteran F, Mendez T, Rapoport M, Guerriero L, Corso A. Controlling false-positive results obtained with the Hodge and Masuda assays for detection of class A carbapenemase in species of *enterobacteriaceae* by incorporating boronic Acid. *J Clin Microbiol*. 2010;48(4):1323-32, <http://dx.doi.org/10.1128/JCM.01771-09>.
 20. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, et al. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing *Klebsiella pneumoniae* isolates by various testing methods. *J Clin Microbiol*. 2010;48(7):2402-6, <http://dx.doi.org/10.1128/JCM.00267-10>.
 21. Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing *Klebsiella pneumoniae* by broth microdilution, Vitek 2, and Etest. *J Clin Microbiol*. 2011;49(5):1795-8, <http://dx.doi.org/10.1128/JCM.02534-10>.